Skip to main content
SpringerLink
Log in

Five Critical Areas that Combat High Costs and Prolonged Development Times for Regenerative Medicine Manufacturing

  • Artificial Tissues (A Atala and JG Hunsberger, Section Editors)
  • Published:
Current Stem Cell Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The purpose of this review is to examine five stages of process improvement in bioengineering of cellular products that could facilitate standardization and accelerate progress through the regulatory pathways and together make such treatments more widely available.

Recent Findings

We present solutions to reduce costs, promote standardization, and enable acceleration through the required regulatory pathways.

Summary

Regenerative medicine-based technologies and products have the potential to revolutionize the practice of medicine and become the next standard of care. We identify current barriers that are limiting the widespread availability of these potential life-saving treatments and platform technologies. One central barrier is the cost of manufacturing these regenerative medicine-based technologies and products at commercial scale.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Radenkovic D, Solouk A, Seifalian A. Personalized development of human organs using 3D printing technology. Med Hypotheses. 2016;87:30–3.

    Article  PubMed  Google Scholar 

  2. •• Culme-Seymour EJ, Mason K, Vallejo-Torres L, Carvalho C, Partington L, Crowley C, et al. Cost of stem cell-based tissue-engineered airway transplants in the United Kingdom: case series. Tissue Eng Part A. 2016;22(3–4):208–13. Provides some of the first cost analysis for manufacutring a tissue-engineered organ

    Article  PubMed  Google Scholar 

  3. Karnieli O, Friedner OM, Allickson JG, Zhang N, Jung S, Fiorentini D, et al. A consensus introduction to serum replacements and serum-free media for cellular therapies. Cytotherapy. 2017;19(2):155–69.

    Article  CAS  PubMed  Google Scholar 

  4. Eaker S, Abraham E, Allickson JG, Brieva TA, Baksh D, Heathman TRJ, et al. Bioreactors for cell therapies: current status and future advances. Cytotherapy. 2017;19:9–18.

    Article  CAS  Google Scholar 

  5. •• Skardal A, Devarasetty M, Kang HW, Mead I, Bishop C, Shupe T, et al. A hydrogel bioink toolkit for mimicking native tissue biochemical and mechanical properties in bioprinted tissue constructs. Acta Biomater. 2015;25:24–34. Illustrates a modular hydrogel system for tailoring bioinks that could be used to create tissue-specific constructs that could be used as disease models, for personalized medicine or drug screening systems.

    Article  CAS  PubMed  Google Scholar 

  6. Chimene D, Lennox KK, Kaunas RR, Gaharwar AK. Advanced bioinks for 3D printing: a materials science perspective. Ann Biomed Eng. 2016;44(6):2090–102.

    Article  PubMed  Google Scholar 

  7. Mir TA, Nakamura M. Three-dimensional bioprinting: toward the era of manufacturing human organs as spare parts for healthcare and medicine. Tissue Eng Part B Rev. 2017.

  8. Panwar A, Tan LP. Current status of bioinks for micro-extrusion-based 3D bioprinting. Molecules. 2016;21(6).

  9. Nebraska Organ Recovery, Acceptable Ischemic Times [Available from: http://www.nedonation.org/donation-guide/organ/acceptable-ischemic-times.]

  10. Mazur P. Freezing of living cells: mechanisms and implications. Am J Phys. 1984;247(3 Pt 1):C125–42.

    CAS  Google Scholar 

  11. Tanaka R, Takahashi N, Nakamura Y, Hattori Y, Ashizawa K, Otsuka M. In-line and real-time monitoring of resonant acoustic mixing by near-infrared spectroscopy combined with chemometric technology for process analytical technology applications in pharmaceutical powder blending systems. Anal Sci. 2017;33(1):41–6.

    Article  PubMed  Google Scholar 

  12. •• Zhang YS, Aleman J, Shin SR, Kilic T, Kim D, Mousavi Shaegh SA, et al. Multisensor-integrated organs-on-chips platform for automated and continual in situ monitoring of organoid behaviors. Proc Natl Acad Sci U S A. 2017;114(12):E2293–E302. Provides a multisensor system that could be developed for providing real-time, non-destructive monitoring of a regenerative medicine manufacturing process. This article focuses on monitoring organoid behaviors which are miniaturized organs.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wake Forest Institute for Regenerative Medicine, Wake Forest University, Winston-Salem, NC, USA

    Joshua G. Hunsberger, Sandeep Goel, Julie Allickson & Anthony Atala

Authors
  1. Joshua G. Hunsberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sandeep Goel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Julie Allickson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anthony Atala
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joshua G. Hunsberger.

Ethics declarations

Conflict of Interest

Joshua G. Hunsberger, Sandeep Goel, Julie Allickson, and Anthony Atala declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Artificial Tissues

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hunsberger, J.G., Goel, S., Allickson, J. et al. Five Critical Areas that Combat High Costs and Prolonged Development Times for Regenerative Medicine Manufacturing. Curr Stem Cell Rep 3, 77–82 (2017). https://doi.org/10.1007/s40778-017-0083-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40778-017-0083-7

Keywords

Search

Navigation